VYNE Therapeutics Inc.
VYNE Therapeutics is committed to solving some of today’s most difficult therapeutic challenges by questioning traditional assumptions and finding better solutions. They develop innovative products for patients, with a focus on their InhiBET™ BET Inhibitor Platform and pipeline products VYN201 and VYN202. The company is rooted in innovation and aims to improve patient outcomes through scientific advancement.
Industries
health-care
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
VYNE Therapeutics Inc.
Menlo Park, California, United States, North America
Products
VYN201
Small-molecule BET bromodomain inhibitor development candidate listed in the company's pipeline.
VYN202
Small-molecule BET bromodomain inhibitor development candidate listed in the company's pipeline.
VYN201
Small-molecule BET bromodomain inhibitor development candidate listed in the company's pipeline.
VYN202
Small-molecule BET bromodomain inhibitor development candidate listed in the company's pipeline.
Expertise Areas
- Epigenetic-targeted therapeutics (BET inhibitors)
- Small-molecule drug discovery
- Preclinical development
- Clinical development
Key Technologies
- BET bromodomain inhibition
- Small-molecule medicinal chemistry
- Preclinical pharmacology and toxicology studies
- Clinical development methodologies